Overview
Description
Coeptis Therapeutics Holdings, Inc. is a biopharmaceutical company that concentrates on developing cell therapy technologies for the treatment of cancer. At the forefront of innovative medical solutions, Coeptis focuses on enhancing the effectiveness of existing oncology therapies, aiming to improve outcomes for patients battling various forms of cancer. One of the defining features of Coeptis Therapeutics is its specialized approach to advancing cell therapy capabilities, which plays a critical role in the burgeoning biopharmaceutical sector. This approach not only supports the development of novel treatment methodologies but also helps to set new benchmarks in the industry. By engaging in strategic collaborations and partnerships, Coeptis Therapeutics is able to leverage cutting-edge scientific research and integrate these advances into practical, clinical applications. With its core capabilities focused on the biotechnology space, Coeptis Therapeutics occupies a pivotal position in the driving wave of therapeutic innovations within the pharmaceutical industry, addressing unmet medical needs and contributing significantly to global healthcare advancements.
About
CEO
Mr. David Mehalick
Employees
5
Address
105 Bradford Road
Suite 420
Wexford, 15090, PA
United States
Suite 420
Wexford, 15090, PA
United States
Phone
724 934 6467
Website
Instrument type
Common stock
Sector
Healthcare
Industry
Biotechnology
Country
United States
MIC code
XNCM